A Phamacoeconomic Analysis of Personalized Dosing vs Fixed Dosing of Pembrolizumab in Firstline PD-L1-Positive Non–Small Cell Lung Cancer

Daniel A. Goldstein, Noa Gordon, Michal Davidescu, Moshe Leshno, Conor E. Steuer, Nikita Patel, Salomon M. Stemmer, Alona Zer

Research output: Contribution to journalArticlepeer-review

78 Scopus citations

Fingerprint

Dive into the research topics of 'A Phamacoeconomic Analysis of Personalized Dosing vs Fixed Dosing of Pembrolizumab in Firstline PD-L1-Positive Non–Small Cell Lung Cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences